Immunogenicity of therapeutics: A matter of efficacy and safety

Expert Opinion on Drug Discovery

Volumn 5, Issue 11, 2010, Pages 1067-1079

  Nechansky, Andreas ^a   Kircheis, Ralf ^b  

^a Vela pharm Entwicklung u Laboranalytik GmbH   (Austria)

^b ViroLogik GmbH   (Germany)

Author keywords

anti drug antibodies; immunogenicity; neutralizing antibodies; patient safety

Indexed keywords

CYTOKINE; EPITOPE; PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BINDING SITE; CELLULAR IMMUNITY; COMPUTER MODEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; EXPERIMENTAL MODEL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; NONHUMAN; ORGANIZATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; SCREENING; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTIGEN PRESENTATION; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY; HUMANS; IMMUNOLOGIC TECHNIQUES; LEGISLATION, DRUG; PATIENT SAFETY; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77958589565     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.514326     Document Type: Review

References (98)

1. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-40
2. Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008;333:1-9
3. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007;28:482-90
4. Check DE. Antibody therapy: clinical trials and tribulations. Nature 2007;26:964-6
5. Leader EB, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008;7:21-39
6. Ritter G, Cohen LS, Williams C Jr, et al. Serological analysis of human anti-human responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001;61:6851-9
7. Tamilvanan S, Raja NL, Sa B, Basu SK. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J Drug Target 2010;18:489-98
8. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005;20(Suppl 6):vi3-9
9. Nagle PC, Nicita CA, Gerdes LA, Schmeichel CJ. Characteristics of and trends in the late-stage biopharmaceutical pipeline. Am J Manag Care 2008;14(4):226-9
10. Ryff JC. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res 1997;17(Suppl 1):S29-33
11. Josic D, Buchacher A, Kannicht C, et al. Degradation products of factor VIII which can lead to increased immunogenicity. Vox Sang 1999;77(Suppl 1):90-9
12. Wadhwa M, Mellstedt H, Small E, Thorpe R. Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF. Dev Biol (Basel) 2003;112:61-7
13. Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004;363:1768-71 (Pubitemid 38698380)
14. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-8
15. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57
16. Schellekens H. Biosimilar therapeutics - what do we need to consider? Nephrol Dial Trans Plus 2009;2:i27-36
17. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006;21:v13-161
18. Shah VP. The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical methods validation. AAPS J 2007;9(1):E43-7
19. Miller JFAF. Immune self-tolerance mechanisms. Transplantation 2001;72:S5-9
20. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16
21. Smolec J, Desilva B, Smith W, et al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm Res 2005;22(9):1425-31
22. EMEA. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Committee for medicinal products for human use (CMPH); 2007
23. International Committee on Harmonisation. Preclinical safety evaluation of biotechnology derived pharmaceuticals. ICH Topic S6
24. FDA. Points to consider in the manufacture and testing of monoclonal antibody products for human use. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research 28 February 1997
25. Shankar E, Shores C, Wagner E, Mire-Sluis AR. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotech 2006;24:273-80
26. Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007;321:1-18
27. Assay Development for Immunogenicity Testing of Therapeutic Proteins. Docket No. FDA-2009-D-0539
28. FDA Draft. Guidance for industry assay development for immunogenicity testing of therapeutic proteins; 2009
29. Nechansky A. HAHA - nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J Pharm Biomed Anal 2010;51:252-4
30. Lofgren JA, Dhandapani S, Pennucci JJ, et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of Panitumumab. J Immunol 2007;178:7467-72
31. Watts C, Powis S. Pathways of antigen processing and presentation. Rev Immunogenet 1999;1(1):60-74
32. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63
33. Camberlain P. Immunogenicity of therapeutic proteins Part 1: causes and clinical manifestations of immunogenicity. Regul Rev 2002;5:4-9
34. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-14
35. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5
36. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52
37. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002;23:201-8
38. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64
39. Werdelin O, Meldal M, Jensen T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc Natl Acad Sci USA 2002;99:9611-13
40. Kircheis R, Nechansky A. Adjuvants in cancer vaccination. In: Benvenuto, editor, Immunologic adjuvant research. Nova Science Publishers, New York, NY, USA; 2009
41. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumor location, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64
42. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005;16:847-62
43. Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010;31:53-9
44. Bali Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006;124:849-63
45. Wang W, Nema S, Teagarden D. Protein aggregation-pathways and influencing factors. Int J Pharm 2010;390:89-99
46. Schnabel CA, Fineberg SE, Kim DD. Immunogenicity of xenopeptide hormone therapies. Peptides 2006;27:1902-10
47. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993;10:307-77
48. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev 2001;46:307-26
49. Sola RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009;98:1223-45
50. Sharma B. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. Biotechnol Adv 2007;25:325-31 (Pubitemid 46498674)
51. Chirino AJ, Mire-Sluis AR. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91
52. Onda M. Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 2009;10:131-9
53. Van Walle I, Lasters I, Stas P. Immunogenicity of therapeutic proteins. Drug Discov World 2006;94-8
54. Stebbings R, Findlay L, Edwards C, et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007;179:3325-31
55. Wang T, Wang Z, Yang R. Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. Crit Rev Oncol Hematol 2010. [Epub ahead of print]
56. Fradkin AH, Carpenter JF, Randolph TW. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 2009;98(9):3247-64
57. Bogaards JJ, Bertrand M, Jackson P, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000;12:1131-52
58. Pearson T, Greiner DL, Shultz LD. Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol 2008;324:25-51
59. Laning J, Burzenski L, Gott B, et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 2010;135(1):84-98
60. Parker AS, Zheng W, Griswold KE, Bailey-Kellogg C. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics 2010;11:180
61. Tangri S, Mothe BR, Eisenbraun J, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 2005;174:3187-96
62. Lazar GA, Desjarlais JR, Jacinto J, et al. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 2007;44:1986-98
63. De Groot AS, Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel 2007;10:332-40
64. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009;131:189-201
65. De Groot AS, Knopp PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modifiation. Dev Biol (Basel) 2005;122:171-94
66. Oh S, Stish BJ, Sachdev D, et al. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res 2009;15(19):6137-47
67. Koren E, De Groot AS, Jawa V, et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 2007;124(1):26-32
68. Van Walle I, Gansemanns Y, Parren P, et al. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007;7:405-18
69. Rubinstein ND, Mayrose I, Pukko T. A machine-learning approach for predicting B-cell epitopes. Mol Immunol 2009;46:840-7
70. Giese C, Lubitz A, Demmler CD, et al. Immunological substance testing on human lymphatic micro-organoids in vitro. J Biotechnol 2010;148:38-45
71. Jones TD, Crompton LJ, Carr FJ, Baker MP. Deimmunization of monoclonal antibodies. Methods Mol Biol 2009;525:405-23
72. Harding FA, Stickler MM, Razo J, Dubridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. Mabs 2010;2(3):1-10
73. Lazar GA, Desjarlais JR, Jacinto J, et al. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 2007;44:1986-98
74. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51
75. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009;61(13):1177-88
76. Weaver EA, Barry MA. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther 2008;19(12):1369-82
77. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16
78. EMEA. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. London, 24 January 2007
79. De Silva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003;20:1885-900
80. Szolar OH, Stranner S, Zinoecker I, et al. Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody. J Pharm Biomed Anal 2006;41(4):1347-53
81. Mashishi T, Gray CM. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med 2002;40(9):903-10
82. Guideline on validation of analytical procedures: definitions and terminology. International Conference of Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use Geneva 1995; 1996
83. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation. A revisit with a decade of progress. Pharm Res 2000;17:1551-7
84. Guidance for the industry. Bioanalytical method validation US. Department of health and human services FDA (CDER) and (CVM) May 2001
85. Ritter N, Advant SJ, Hennessey J, et al. What is method qualification? BioProcess Intern 2004;9:32-46
86. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotech 2002;3:349-60
87. Shah VP, Midha KK, Dighe SV, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309-12
88. Wadhwa M, Thorpe R. Strategies and assays for the assessment of unwanted immunogenicity. J Immunotoxicol 2006;3:115-21
89. Mire-Sluis AR, Barrett YC, Davanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16
90. Davis GC, Beals JM, Johnson C, et al. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability. Curr Med Res Opin 2009;25:1655-61
91. Rup B, O'Hara D. Critical ligand binding reagent preparation/selection: when specificity depends on reagents. AAPS J 2007;9(2):E148-55
92. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21(Suppl 5):v9-12
93. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 2007;24:1962-73 (Pubitemid 47389236)
94. Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007;321:1-18
95. Bertolotto A. Implications of neutralizing antibodies on therapeutic efficacy. J Neurol Sci 2009;277(Suppl 1):S29-32
96. Shanker G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007;25:555-61
97. Findlay JWA, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000;21:1249-73
98. Meager A, Cludts I, Thorpe R, Wadhwa M. Are neutralizing anti-GM-CSF autoantibodies present in all healthy persons? Blood 2010;115(2):433-4